Quantcast
Last updated on April 17, 2014 at 15:37 EDT

Latest Metformin Stories

2013-06-06 11:37:43

Manufacturer's dossier did not contain suitable data for any therapeutic indication Dapagliflozin (trade name: Forxiga) has been approved in Germany since November 2012 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy. No such...

2013-05-28 16:26:28

NEWARK, Calif., May 28, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Jefferies 2013 Global Healthcare Conference at the Grand Hyatt in New York City. The presentation at the Jefferies conference is scheduled for 4:30 pm EDT (1:30 pm PDT) on Monday, June 3, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be...

2013-05-27 10:49:17

The news about youth and diabetes keeps getting worse. The latest data from the national TODAY diabetes study shows that children who develop Type 2 diabetes are at high risk to develop heart, kidney and eye problems faster and at a higher rate than people who acquire Type 2 diabetes as adults. "Once these kids have Type 2 diabetes, they seem to be at very high risk for early complications when compared to adults," said Jane Lynch, M.D., professor of pediatric endocrinology in the School...

2013-05-20 08:26:55

SAN DIEGO, May 20, 2013 /PRNewswire/ -- Enrollment of patients with Type 2 diabetes is underway in Elcelyx Therapeutics' Phase 2b dose-finding clinical trial of product candidate NewMet(TM), a delayed-release formulation of generic metformin, the foundational treatment for Type 2 diabetes. Elcelyx expects to complete enrollment of 240 patients in the multicenter U.S. program in June. Results of the trial's primary endpoint of change in fasting plasma glucose are expected in late summer, and...

2013-05-16 08:27:46

NEWARK, Calif., May 16, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the UBS Global Healthcare Conference at the Sheraton New York Hotel in New York City. The presentation at the UBS conference is scheduled for 10 am EDT (7 am PDT) on Tuesday, May 21, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived...

2013-05-02 23:25:22

DrugRisk is the Web´s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com Los Angeles, CA (PRWEB) May 02, 2013 The diabetes drug safety advocates at DrugRisk.com are announcing new information on the site for those taking the medication Januvia. A recent study suggests the drug may have higher occurrence rates of pancreatitis and pancreatic cancer than traditional pills****. DrugRisk was created to improve patient...

2013-05-01 08:31:15

NEWARK, Calif., May 1, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2013 financial results after the market closes on Wednesday, May 8, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live...

2013-04-29 16:30:05

NEW YORK, April 29, 2013 /PRNewswire/ -- Commenting on a $6.5 million dollar verdict reached this past Friday in a Los Angeles courtroom against Takeda Pharmaceuticals for injuries arising from the plaintiffs' ingestion of Takeda's blockbuster selling diabetes drug, Actos®, Napoli Bern Ripka Shkolnik, LLP Senior Partner Hunter Shkolnik described the verdict as "a disaster for Takeda". In the California trial, a jury found that in marketing Actos®, which has been linked to bladder...

2013-04-29 16:01:28

Drug manufacturer did not submit suitable data in its dossier The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products” (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this fixed combination product offers an added...

2013-03-13 16:26:08

NEWARK, Calif., March 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Roth Capital Partners 25th Annual Growth Stock Conference at the Ritz-Carlton Hotel in Dana Point, California. The presentation at the Roth conference is scheduled for 11:30 am PDT (2:30 pm EDT) on Tuesday March 19, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A...